<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04109924</url>
  </required_header>
  <id_info>
    <org_study_id>I 444019</org_study_id>
    <secondary_id>P30CA016056</secondary_id>
    <nct_id>NCT04109924</nct_id>
  </id_info>
  <brief_title>TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study</brief_title>
  <official_title>A Phase II Study of TAS-102, Irinotecan and Bevacizumab in Pre-Treated Metastatic Colorectal Cancer (TABAsCO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Comprehensive Cancer Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well TAS-102, irinotecan, and bevacizumab work in treating&#xD;
      patients with pre-treated colorectal cancer that has spread to other places in the body&#xD;
      (metastatic) or cannot be removed by surgery (unresectable). Drugs used in chemotherapy, such&#xD;
      as TAS-102, work in different ways to stop the growth of tumor cells, either by killing the&#xD;
      cells, by stopping them from dividing, or by stopping them from spreading. Irinotecan may&#xD;
      stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.&#xD;
      Immunotherapy with bevacizumab, may induce changes in body's immune system and may interfere&#xD;
      with the ability of tumor cells to grow and spread. Giving TAS-102, irinotecan, and&#xD;
      bevacizumab may work better in treating patients with colorectal cancer compared to&#xD;
      traditional chemotherapy and bevacizumab.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. Determine the median progression free survival (PFS) benefit of leucovorin calcium,&#xD;
      5-fluorouracil, and irinotecan (FOLFIRI) naive patients treated with trifluridine and&#xD;
      tipiracil hydrochloride (TAS-102) + irinotecan + bevacizumab as compared to historic control&#xD;
      groups treated with FOLFIRI + bevacizumab.&#xD;
&#xD;
      SECONDARY OBJECTIVE:&#xD;
&#xD;
      I. Estimate the objective response rate (ORR), median overall survival (OS), and adverse&#xD;
      event (AE) profile.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive irinotecan intravenously (IV) over 90 minutes and bevacizumab IV over 30-90&#xD;
      minutes on days 1 and 15. Patients also receive trifluridine and tipiracil hydrochloride&#xD;
      orally (PO) twice daily (BID) on days 2-6 and 16-20. Cycles repeat every 28 days in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 30 days and then every 6&#xD;
      months for up to 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 27, 2019</start_date>
  <completion_date type="Anticipated">April 22, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 22, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median progression free survival (PFS)</measure>
    <time_frame>From treatment until disease progression, death due to disease, or last follow-up, assessed up to 2 years post-treatment</time_frame>
    <description>Will be assessed via the Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 guidelines. The PFS will be summarized using standard Kaplan-Meier methods, where estimates of the median PFS and 6/12-month PFS rates will be obtained with 90% confidence intervals.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>Up to 2 years post-treatment</time_frame>
    <description>ill be tabulated based upon RECIST v1.1 criteria. Will be summarized using frequencies and relative frequencies. Using Jeffrey's prior method, a 90% confidence interval about the true ORR will be obtained for each treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median overall survival (OS)</measure>
    <time_frame>From the date of enrollment to the time of death, assessed up to 2 years post-treatment</time_frame>
    <description>OS will be summarized using standard Kaplan-Meier methods; where estimates of the median survival and 12-month rates are obtained with 90% confidence intervals</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-specific survival (DSS)</measure>
    <time_frame>From treatment until death due to disease or last follow-up, assessed up to 2 years post-treatment</time_frame>
    <description>DSS will be summarized using standard Kaplan-Meier methods; where estimates of the median survival and 12-month rates are obtained with 90% confidence intervals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aggregate rates of adverse events</measure>
    <time_frame>Up to 30 days after last dose of study drug</time_frame>
    <description>easured by Common Terminology Criteria for Adverse Events (CTCAE) v5.0 and recorded to objectively measure toxicities of the combination therapy. Treatment related adverse events (as per CTCAE v5.0) will be summarized by grade using frequencies and</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Advanced Colorectal Carcinoma</condition>
  <condition>Metastatic Colon Adenocarcinoma</condition>
  <condition>Metastatic Rectal Adenocarcinoma</condition>
  <condition>Recurrent Colon Adenocarcinoma</condition>
  <condition>Recurrent Colorectal Adenocarcinoma</condition>
  <condition>Recurrent Rectal Adenocarcinoma</condition>
  <condition>Stage III Colon Cancer AJCC v8</condition>
  <condition>Stage III Colorectal Cancer AJCC v8</condition>
  <condition>Stage III Rectal Cancer AJCC v8</condition>
  <condition>Stage IIIA Colon Cancer AJCC v8</condition>
  <condition>Stage IIIA Colorectal Cancer AJCC v8</condition>
  <condition>Stage IIIB Colorectal Cancer AJCC v8</condition>
  <condition>Stage IIIB Rectal Cancer AJCC v8</condition>
  <condition>Stage IIIC Colon Cancer AJCC v8</condition>
  <condition>Stage IIIC Colorectal Cancer AJCC v8</condition>
  <condition>Stage IV Colon Cancer AJCC v8</condition>
  <condition>Stage IVA Colorectal Cancer AJCC v8</condition>
  <condition>Stage IVA Rectal Cancer AJCC v8</condition>
  <condition>Stage IVB Colon Cancer AJCC v8</condition>
  <condition>Stage IVB Colorectal Cancer AJCC v8</condition>
  <condition>Stage IVB Rectal Cancer AJCC v8</condition>
  <condition>Stage IVC Colon Cancer AJCC v8</condition>
  <condition>Stage IVC Colorectal Cancer AJCC v8</condition>
  <condition>Stage IVC Rectal Cancer AJCC v8</condition>
  <condition>Unresectable Colon Adenocarcinoma</condition>
  <condition>Unresectable Colorectal Carcinoma</condition>
  <condition>Unresectable Rectal Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Treatment (irinotecan, bevacizumab, TAS-102)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive irinotecan IV over 90 minutes and bevacizumab IV over 10 minutes on days 1 and 15. Patients also receive trifluridine and tipiracil hydrochloride PO BID on days 2-6 and 16-20. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (irinotecan, bevacizumab, TAS-102)</arm_group_label>
    <other_name>(+)-(4S)-4</other_name>
    <other_name>11-diethyl-4-hydroxy-9-[(4-piperidino-piperidino)carbonyloxy]-1H-pyrano[3'',4'':6,7]indolizino[1,2-b]quinol-3,14,(4H,12H)-dione</other_name>
    <other_name>(+)-7-ethyl-10-hydroxycamptothecine 10-[1,4''-bipiperidine]-1''-carboxylate,</other_name>
    <other_name>616348,</other_name>
    <other_name>7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin</other_name>
    <other_name>728073</other_name>
    <other_name>97682-44-5</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (irinotecan, bevacizumab, TAS-102)</arm_group_label>
    <other_name>216974-75-3</other_name>
    <other_name>704865</other_name>
    <other_name>Anti-VEGF</other_name>
    <other_name>Anti-VEGF Humanized Monoclonal Antibody</other_name>
    <other_name>Anti-VEGF rhuMAb</other_name>
    <other_name>Avastin</other_name>
    <other_name>Bevacizumab awwb</other_name>
    <other_name>Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain,</other_name>
    <other_name>Dimer</other_name>
    <other_name>Recombinant Humanized Anti-VEGF Monoclonal Antibody</other_name>
    <other_name>rhuMab-VEGF</other_name>
    <other_name>SCT501</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trifluridine and Tipiracil Hydrochloride</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (irinotecan, bevacizumab, TAS-102)</arm_group_label>
    <other_name>733030-01-8</other_name>
    <other_name>Lonsurf</other_name>
    <other_name>TAS 102</other_name>
    <other_name>TAS-102</other_name>
    <other_name>Thymidine</other_name>
    <other_name>Alpha</other_name>
    <other_name>Mixt. with 5-Chloro-6-((2-imino-1-pyrrolidinyl)methyl)-2,4(1H,3H)-pyrimidinedione Monohydrochloride</other_name>
    <other_name>Tipiracil Hydrochloride Mixture with Trifluridine</other_name>
    <other_name>Trifluridine/Tipiracil,</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Advanced colorectal cancer (metastatic or unresectable): Histologically or cytological&#xD;
             proven adenocarcinoma of the colon or rectum which is metastatic or otherwise&#xD;
             incurable&#xD;
&#xD;
          -  Prior treatment with a fluoropyrimidine (5-fluorouracil [5-FU] or capecitabine) and&#xD;
             oxaliplatin in the metastatic/unresectable setting OR, recurrence within 12 months of&#xD;
             adjuvant therapy with a regimen that included oxaliplatin&#xD;
&#xD;
          -  Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1&#xD;
&#xD;
          -  Hemoglobin &gt;= 9 g/dL&#xD;
&#xD;
          -  Absolute neutrophil count &gt;= 1500/mm^3&#xD;
&#xD;
          -  Platelet count &gt;= 100,000/mm^3&#xD;
&#xD;
          -  Creatinine &lt; 1.5 upper limit of normal (ULN) or if &gt;= 1.5 x ULN creatinine clearance&#xD;
             (CRCL) &gt;= 30 mL/min (by Cockcroft-Gault)&#xD;
&#xD;
          -  Bilirubin &lt; 1.5 x ULN&#xD;
&#xD;
          -  Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =&lt; 2.5 x ULN or =&lt; 5 x&#xD;
             ULN if with hepatic metastases&#xD;
&#xD;
          -  Have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1&#xD;
             criteria present&#xD;
&#xD;
          -  Participants of child-bearing potential must agree to use adequate contraceptive&#xD;
             methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study&#xD;
             entry. Should a woman become pregnant or suspect she is pregnant while she or her&#xD;
             partner is participating in this study, she should inform her treating physician&#xD;
             immediately&#xD;
&#xD;
          -  Participant must understand the investigational nature of this study and sign an&#xD;
             Independent Ethics Committee/Institutional Review Board approved written informed&#xD;
             consent form prior to receiving any study related procedure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with TAS-102 or irinotecan&#xD;
&#xD;
          -  Anti-cancer therapy within 2 weeks of the planned first dose of study medication&#xD;
&#xD;
          -  Unresolved toxicities from prior therapy of &gt; grade 1, excluding alopecia or similar&#xD;
             toxicities which are not deemed to be clinically significant or put the participant at&#xD;
             greater risk. Grade 2 neuropathy is permitted&#xD;
&#xD;
          -  Major surgery within 4 weeks of anticipated start of therapy&#xD;
&#xD;
          -  Uncontrolled hypertension: systolic blood pressure &gt;= 150, diastolic blood pressure &gt;=&#xD;
             100&#xD;
&#xD;
          -  Unstable angina, symptomatic congestive heart failure or cardiac arrhythmia requiring&#xD;
             anti-arrhythmic therapy (beta-blockers, calcium channel blockers and digoxin are&#xD;
             allowed)&#xD;
&#xD;
          -  Arterial or venous thrombotic or embolic events within 3 months of study initiation,&#xD;
             unless well controlled on stable anti-coagulation for &gt;= 2 weeks. This excludes&#xD;
             uncomplicated catheter associated venous thrombosis&#xD;
&#xD;
          -  History of cerebrovascular or myocardial ischemia within 6 months of initiation&#xD;
&#xD;
          -  National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)&#xD;
             version (v) 5.0 grade 3 or greater hemorrhage within the past 4 weeks&#xD;
&#xD;
          -  Proteinuria &gt;= 2+, unless 24 hour urine collection demonstrates =&lt; 1 g of protein OR&#xD;
             spot protein: creatinine demonstrates a ratio of =&lt; 1&#xD;
&#xD;
          -  Untreated brain metastases&#xD;
&#xD;
          -  History of abnormal glucuronidation of bilirubin (Gilbert's syndrome)&#xD;
&#xD;
          -  History of second primary malignancy within 3 years prior to enrollment, excluding&#xD;
             in-situ cervical carcinoma, non-melanoma skin cancer or malignancy of equivalent risk&#xD;
             which is highly unlikely to require systemic treatment in the next 2 years&#xD;
&#xD;
          -  Have known active infection which would heighten the risk of complications&#xD;
&#xD;
          -  Pregnant or nursing female participants&#xD;
&#xD;
          -  Unwilling or unable to follow protocol requirements&#xD;
&#xD;
          -  Any condition which in the investigator's opinion deems the participant an unsuitable&#xD;
             candidate to receive study drug&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christos Fountzilas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christos Fountzilas</last_name>
    <phone>i-800-767-9355</phone>
    <email>askroswell@roswellpark.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iman Imanirad, MD</last_name>
      <phone>813-745-4673</phone>
      <email>Iman.Imanirad@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Iman Imanirad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick M Boland, MD</last_name>
      <phone>732-235-7066</phone>
      <email>pb564@cinj.rutgers.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ask Roswellpark</last_name>
      <phone>800-767-9355</phone>
    </contact>
    <investigator>
      <last_name>Christos Fountzilas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Namrata Vijayvergia, MD</last_name>
      <phone>215-214-1676</phone>
      <email>namrata.vijayvergia@fccc.edu</email>
    </contact>
    <investigator>
      <last_name>Namrata Vijayvergia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>September 27, 2019</study_first_submitted>
  <study_first_submitted_qc>September 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2019</study_first_posted>
  <last_update_submitted>July 22, 2021</last_update_submitted>
  <last_update_submitted_qc>July 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Rectal Neoplasms</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trifluridine</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Antineoplastic Agents, Immunological</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>10-hydroxycamptothecin</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

